Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of QY201 tablets in moderate-to-severe atopic dermatitis
CTR20222115Phase 2Active
- Sponsor
- Origin Biosciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of qy201 in atopic dermatitis (AD), sponsored by Origin Biosciences. Started Nov 2022; status: active.
02
Drugs
qy201
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20222115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222115.